ClinicalTrials.gg
CompletedNCT01645189GC1111Updated Jul 8, 2014

Safety and Efficacy of Hunterase

A Phase 3 interventional study of Hunterase in Hunter Syndrome, sponsored by Green Cross Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
Up to 5 Years
Sex
Male
01

Study summary

The objective of this study is to determine the safety and efficacy of once weekly dosing of idursulfase-beta 0.5mg/kg administered by intravenous(IV) infusion for Hunter syndrome patients \< 6 years old.

02

Conditions studied

  • Hunter Syndrome

Keywords

  • Hunter syndrome
  • idursulfase-beta
  • Hunterase
  • GC1111
03

In context

Mucopolysaccharidosis II

77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.

This study's enrollment of 6 is below the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.

Browse Mucopolysaccharidosis II studies →

Lead sponsor

Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has a diagnosis of Hunter syndrome based upon biochemical criteria:

    • as measured in plasma, leukocytes, or fibroblasts,

      • a deficiency in iduronate-2-sulfatase (I2S) enzyme activity of ≤ 10 % of the lower limit of the normal range
    • That corresponds to one or more of the following:

      • a normal enzyme activity level of one other sulfatase
      • Confirmed as MPS2 by genetic test results
      • shows clinical symptoms/ visible signs of MPS2
  2. \< 6 years old and male
  3. Patients who are able to comply with the study requirements
  4. The patient's parent(s), or patient's legal guardian must have given voluntary written consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. The patient has had a tracheostomy
  2. The patient has known severe or shock to any of the components of idursulfase
  3. The patient has received treatment with another therapy within 30 days prior to enrollment
  4. History of a stem cell transplant
  5. The patient has known severe hypersensitivity or shock to any of the components of test drug( etc)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Test drug

    Idursulfase-beta

    Biological: Hunterase

Interventions

  • BiologicalHunterase

    once weekly, 0.5mg/kg IV infusion

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: One year

Secondary outcomes

  1. change of anti-idursulfase-beta antibody status

    Time frame: baseline and one year

  2. Percent Change of Urine GAG

    Time frame: baseline to 53 weeks

07

Study locations

1 site
  • Samsug Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2012
First posted
Jul 20, 2012
Start
Jul 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01645189
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Jul 2012
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Jul 8, 2014

Study contacts

Dong-Kyu Jin
principal investigator · Samsung medical center, Seoul, Republic of Korea

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idursulfase beta

Start the discussion